XCEED’S NOVOSKIN SHOWS PRE-CLINICAL EFFICACY IN SHEEP
December 22nd 2007 05:16
Biotech Daily
Friday December 21, 2007
Daily news on ASX-listed biotechnology companies
Friday December 21, 2007
Daily news on ASX-listed biotechnology companies
* ASX UP, BIOTECHS EVEN: PSIVIDA UP 7%, TISSUE THERAPIES DOWN 12.5%
* BIOTECH DAILY SEASON’S GREETINGS; PUBLICATION TIMES
* XCEED’S NOVOSKIN SHOWS PRE-CLINICAL EFFICACY IN SHEEP
* SELECT CLAIMS NEW MULTI-INFLUENZA VACCINE CANDIDATE
* OMI SECURES $US4.3m FIRST SAFE SYRINGE SALES ORDER
* FDA WARNING AN OPPORTUNITY FOR STARPHARMA’S VAGINAL GEL
* ANTISENSE COMPLETES ENROLMENT IN MS PHASE IIa TRIAL
* PROGEN SAYS HOLIDAYS DELAY PHASE III LIVER CANCER TRIAL
* AGENIX PART OF $230k FEDERAL MONOCLONAL ANTIBODY GRANT
* FEDERAL COURT CLEARS VISIOMED, CLINICAL CELL MERGER
* COCHLEAR ‘VIGOROUSLY’ DEFENDS PATENT COMPLAINT
* VIRALYTICS SHARE PLAN RAISES $1.7m, SO FAR
* EASTLAND MERGES EAST COAST ‘UNDERPERFORMERS’
* AGENIX PAYS CEO DR STEPHEN PHUA $400k, PLENTY OF PERKS
* CITICORP SELLS 11m ARANA SHARES
THE MARKET
Fourteen of the Biotech Daily Top 40 stocks were up, 14 fell, 10 traded unchanged and two were untraded.
Psivida was best, up 0.6 cents or 7.23 percent to 8.9 cents on small volumes, followed by Alchemia up four cents or 6.45 percent to 66 cents.
Tissue Therapies led the falls, down five cents or 12.5 percent to 35 cents on small volumes followed by Antisense down 10.64 percent, Neuren down 10 percent and Novogen down 9.09 percent.
subscribe to Biotech Daily at the link above
XCEED CAPITAL (FORMERLY XCEED BIOTECHNOLOGY)
Xceed subsidiary, Polynovo Biomaterials has “demonstrated the efficacy of the Novoskin’s dermal matrix prototype in a [preclinical] wound model” in sheep.
Xceed said the Novoskin dermal matrix product would be used to treat major skin loss and was made from Novosorb, a material also used for repairing bone and blood vessels.
The sheep study was commissioned by Novoskin a Polynovo joint venture with burns surgeon Dr John Greenwood.
The study and data analysis were performed by an independent accredited testing facility and “demonstrated the efficacy of the Novoskin’s dermal matrix prototype in a wound model”.
Xceed said the study involved assessment of a dermal matrix prototype made from Novosorb compared with natural healing and a global market leading dermal matrix product and said natural healing resulted in severe contraction and scarring in all six wound sites.
The Novosorb matrix and the current market leading product both resisted contraction with a reduction in the volume of scar tissue to similar degrees.
A normal epidermis, or outer layer of skin, quickly formed over the Novosorb matrix which led to complete healing of the wound site in all cases. This would create an option for the surgeon to apply skin grafts earlier and obtain better acceptance.
The current market leading product formed an ulcerated epidermis in all six wound sites.
No evidence of clinical infection was observed in the Novosorb matrix filled wounds.
The current market leading product displayed infection in two of six wounds created for this study.
Dr Greenwood said the dermal matrix in both sheep wound model and human cellular studies “demonstrated proof of design concept”.
“The outstanding results from the prototype matrix gives us confidence that with continued optimization our product will compete favorably with the existing dermal matrix products,” Dr Greenwood said.
“The cellular studies also give us confidence that generational products can lead to replacement of the role of skin grafts,” he said.
“These products would reduce pain, scarring and enhance survival prospects of many patients,” Dr Greenwood said.
Polynovo chief executive officer Dr Ian Griffiths said that optimization of the matrix and validation of the manufacturing were planned for early 2008.
“We will continue this study with statistically relevant numbers in mid 2008,” Dr Griffiths said.
“We believe this will allow us to proceed with our application for human trials and commercialization of the first generation products,” he said.
Separately, Xceed changed its name from Xceed Biotechnology to Xceed Capital.
Xceed climbed three cents or 24 percent to 15.5 cents.
Subscribe to Biotech Daily at the link above
| 47 |
| Vote |
Add To: 
subscribe to this blog